Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

We present efficacy and safety from STARGLO, with 3 years of follow-up, including in clinically relevant subgroups.

我们提供了STARGLO试验的疗效和安全性数据，包括3年的随访时间，以及在临床相关亚组中的分析。

After a median OS follow-up of 35.1 months (data cutoff: 1 May 2025), Glofit-GemOx continued to demonstrate favorable outcomes vs R-GemOx, respectively: median OS, 25.5 vs 12.5 months (hazard ratio[HR], 0.60; 95% confidence interval[CI], 0.4-0.8); median progression-free survival, 14.4 vs 3.3 months (HR, 0.41; 95% CI, 0.3-0.6); complete response rate, 58.5% vs 25.3%.

在中位总生存期（OS）随访35.1个月后（数据截止日期：2025年5月1日），Glofit-GemOx与R-GemOx相比，继续显示出有利的临床结果：中位总生存期分别为25.5个月和12.5个月（风险比[HR]，0.60；95%置信区间[CI]，0.4-0.8）；中位无进展生存期分别为14.4个月和3.3个月（HR，0.41；95% CI，0.3-0.6）；完全缓解率分别为58.5%和25.3%。

Glofit-GemOx was particularly efficacious in the second-line (2L) vs third-line or later setting (3-year OS rate, 54.6% [95% CI, 45.2-64.0] vs 33.2% [95% CI, 21.2-45.3]).

Glofit-GemOx在二线（2L）治疗中的疗效特别显著，与三线或更晚治疗相比，3年总生存率分别为54.6%（95% CI，45.2-64.0）和33.2%（95% CI，21.2-45.3）。

In the 2L setting, among patients with primary refractory disease or early treatment failure, the 36-month OS rate was 46.1% (95% CI, 35.2-56.9) with Glofit-GemOx vs 16.5% (95% CI, 3.4-29.6) with R-GemOx.

在二线治疗中，对于原发性难治性疾病或早期治疗失败的患者，Glofit-GemOx组的36个月总生存率为46.1%（95%置信区间，35.2-56.9），而R-GemOx组为16.5%（95%置信区间，3.4-29.6）。

Glofit-GemOx was favorable over R-GemOx regardless of patient age, with consistent efficacy observed across age categories, including in older patients (aged ≥75 years).

无论患者年龄如何，Glofit-GemOx均优于R-GemOx，且在各个年龄组中均观察到一致的疗效，包括在老年患者（年龄≥75岁）中。

No new safety signals were identified.

未发现新的安全信号。

With extended follow-up, fixed-duration Glofit-GemOx continues to demonstrate superior survival vs R-GemOx in ASCT-ineligible patients with R/R DLBCL, with favorable outcomes pronounced in the 2L setting, and consistent across subgroups including older patients and those with early relapsing disease.

随着随访时间的延长，对于不适合自体干细胞移植（ASCT）的复发/难治性弥漫大B细胞淋巴瘤（R/R DLBCL）患者，固定疗程的Glofit-GemOx与R-GemOx相比，继续显示出优越的生存率，特别是在二线治疗（2L）中的疗效更为显著，并且在包括老年患者和早期复发疾病患者在内的各个亚组中结果一致。

These data support Glofit-GemOx as an effective off-the-shelf treatment with curative potential in R/R DLBCL.

这些数据支持Glofit-GemOx作为一种有效的现成治疗方案，具有治疗复发/难治性弥漫大B细胞淋巴瘤（R/R DLBCL）的潜力。

This trial was registered at www.clinicaltrials.gov as NCT04408638.

这项试验已在www.clinicaltrials.gov上注册，注册号为NCT04408638。